Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.31 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.30 |
| ▸ | PPIA | P62937 | 2/20 | 0.30 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15727225 | 0.93 | CTSD (0.32) | CTSDKMT2A | |
| SCHEMBL15727251 | 0.92 | CTSD (0.33) | CTSDKMT2A | |
| SCHEMBL23736270 | 0.88 | KMT2A (0.32) | KMT2A | |
| SCHEMBL23736283 | 0.82 | KMT2A (0.31) | KMT2A | |
| SCHEMBL23736271 | 0.81 | ITGB3 (0.34) | KMT2APPIA | |
| SCHEMBL23736280 | 0.81 | KMT2A (0.33) | KMT2A | |
| SCHEMBL15727299 | 0.79 | CTSD (0.53) | CTSDBACE1 | |
| SCHEMBL13640163 | 0.75 | KMT2A (0.40) | KMT2AANPEPLNPEP | |
| SCHEMBL23736109 | 0.74 | KMT2A (0.32) | KMT2APSMB9 | |
| SCHEMBL15727316 | 0.73 | CTSD (0.53) | CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CTSD 271/4885KMT2A 3283/4885MEN1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.